1887

Abstract

In a pilot study, the feasibility of immune whey protein concentrate (40 %; immune WPC-40) to aid the prevention of relapse of diarrhoea was evaluated. Immune WPC-40 was made from milk after immunization of Holstein–Frisian cows with inactivated toxins and killed whole-cell . Immune WPC-40 contained a high concentration of specific sIgA antibodies, and was effective in neutralizing the cytotoxic effect of toxins in cell assays . Immune WPC-40 conferred protection from otherwise lethal -associated caecitis in hamsters. To obtain preliminary data in humans, 16 patients (10 male; median 57 years) with toxin- and culture-confirmed diarrhoea were enrolled in an uncontrolled cohort study. Nine had a history of relapsing diarrhoea. After completion of standard antibiotic treatment, the patients received immune WPC-40 TID for 2 weeks; it was well tolerated and no treatment-related adverse effects were observed. In all but one case, toxins had disappeared from the faeces upon completion of treatment. During a follow-up period of median 333 days (range 35 days to 1 year), none of the patients had suffered another episode of diarrhoea. These preliminary data suggest that immune whey protein concentrate-40 may be of help in the prevention of relapse of diarrhoea.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.45773-0
2005-02-01
2020-09-24
Loading full text...

Full text loading...

/deliver/fulltext/jmm/54/2/JM540217.html?itemId=/content/journal/jmm/10.1099/jmm.0.45773-0&mimeType=html&fmt=ahah

References

  1. Aas J., Gessert C. E., Bakken J. S. 2003; Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36:580–585 [CrossRef]
    [Google Scholar]
  2. Aspinall S. T., Hutchinson D. N. 1992; New selective medium for isolating Clostridium difficile from feces. J Clin Pathol 45:812–814 [CrossRef]
    [Google Scholar]
  3. Barbut F., Petit J.-C. 2001; Epidemiology of Clostridium difficile -associated infections. Clin Microbiol Infect 8:405–411
    [Google Scholar]
  4. Bennett B. G., Gorbach S. L., Goldin B. R., Chang T. W., Laughon B. E., Greenough W. B. III, Bartlett J. G. 1996; Treatment of relapsing Clostridium difficile diarrhoea with Lactobacillus GG. Nutrition Today 31:Suppl35–38 [CrossRef]
    [Google Scholar]
  5. Bignardi G. E. 1998; Risk factors for Clostridium difficile infection. J Hospital Infect 40:1–15
    [Google Scholar]
  6. Burbige E. J., Milligan F. D. 1975; Pseudomembranous colitis.Association with antibiotics and therapy with cholestyramine. JAMA 231:1157–1158 [CrossRef]
    [Google Scholar]
  7. Chang T. W., Bartlett J. G., Gorbach S. L., Onderdonk A. B. 1978; Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun 20:526–529
    [Google Scholar]
  8. Fagarasan S., Honjo T. 2003; Intestinal IgA synthesis: regulation of front-line body defense. Nature Rev Immunol 3:63–72 [CrossRef]
    [Google Scholar]
  9. Fedorko D. P., Williams E. C. 1997; Use of cycloserine-cefoxiton-fructose agar and l-prolin-aminopeptidase PRO discs in the rapid identification of Clostridium difficile . J Clin Microbiol 35:1258–1259
    [Google Scholar]
  10. Kelly C. P., Pothoulakis C., Lamont J. T. 1994; Clostridium difficile colitis. N Engl J Med 330:257–262 [CrossRef]
    [Google Scholar]
  11. Kelly C. P., Pothoulakis C., Vavva F., Castagliuolo I., Bostwick E. F., O'Keane J. C., Keates S., LaMont J. T. 1996; Anti- Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C.difficile toxins. Antimicrob Agents Chemother 40:373–379
    [Google Scholar]
  12. Kelly C. P., Chetham S., Keates S., Bostwick E. F., Roush A. M., Castagliuolo I., LaMont J. T., Pothoulakis C. 1997; Survival of anti- Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother 41:236–241
    [Google Scholar]
  13. Kurtz C. B., Cannon E. P., Brezzani A. & 12 other authors; 2001; GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 45:2340–2347 [CrossRef]
    [Google Scholar]
  14. Leung D. Y., Kelly C. P., Boguniewicz M., Pothoulakis C., LaMont J. T., Flores A. 1991; Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 118:633–637 [CrossRef]
    [Google Scholar]
  15. Lyerly D. M., Bostwick E. F., Binion S. B., Wilkins T. D. 1991; Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 59:2215–2218
    [Google Scholar]
  16. McFarland L. V., Mulligan M. E., Kwok R. Y. Y., Stamm W. E. 1989; Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320:204–210 [CrossRef]
    [Google Scholar]
  17. McFarland L. V., Surawicz C. M., Greenberg R. N., Fekety R., Elmer G. W., Moyer K. A., Melcher S. A., Bowen K. E., Cox J. L., Noorani Z. 1994; A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271:1913–1918 [CrossRef]
    [Google Scholar]
  18. McNulty C., Logan M., Donald I. P., Ennis D., Taylor D., Baldwin R. N., Bannerjee M., Cartwright K. A. 1997; Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 40:707–711 [CrossRef]
    [Google Scholar]
  19. Minekus M., Havenaar R. 1996; In Vitro Model of an In Vivo Digestive Tract. United States Patent no. 5,525,305:
    [Google Scholar]
  20. Spencer R. C. 1998; Clinical impact and associated costs of Clostridium difficile -associated disease. J Antimicrob Chemother 41:5–12 [CrossRef]
    [Google Scholar]
  21. Stoddart B., Wilcox M. H. 2001; Clostridium difficile . Curr Opin Infect Dis 15:513–518
    [Google Scholar]
  22. Sullivan N. M., Pellett S., Wilkins T. D. 1982; Purification and characterization of Toxin A and B of Clostridium difficile . Infect Immun 35:1032–1040
    [Google Scholar]
  23. Surawicz C. M., Elmer G. W., Speelman P., McFarland L. V., Chinn J., van Belle G. 1989; Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii : a prospective study. Gastroenterology 96:981–988
    [Google Scholar]
  24. Taylor N. S., Bartlett J. G. 1980; Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 141:92–97 [CrossRef]
    [Google Scholar]
  25. Tedesco F. J. 1982; Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 77:220–221
    [Google Scholar]
  26. Thomas M. R., Litin S. C., Osmon D. R., Corr A. P., Weaver A. L., Lohse C. M. 2001; Lack of effect of Lactobacillus GG on antibiotic-associated diarrhoea: a randomized, placebo-controlled trial. Mayo Clin Proc 76:883–889 [CrossRef]
    [Google Scholar]
  27. Warny M., Fatimi A., Bostwick E. F., Laine D. C., Lebel F., LaMont J. T., Pothoulakis C., Kelly C. P. 1999; Bovine immunoglobulin concentrate- Clostridium difficile retains C.difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 44:212–217 [CrossRef]
    [Google Scholar]
  28. Wilcox M. H., Cunniffe J. G., Trundle C., Redpath C. 1996; Financial burden of hospital acquired Clostridium difficile infection. J Hosp Infect 34:23–30 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.45773-0
Loading
/content/journal/jmm/10.1099/jmm.0.45773-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error